ATE254172T1 - Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase - Google Patents

Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase

Info

Publication number
ATE254172T1
ATE254172T1 AT94103057T AT94103057T ATE254172T1 AT E254172 T1 ATE254172 T1 AT E254172T1 AT 94103057 T AT94103057 T AT 94103057T AT 94103057 T AT94103057 T AT 94103057T AT E254172 T1 ATE254172 T1 AT E254172T1
Authority
AT
Austria
Prior art keywords
alzheimer
preventive
disease
protein kinase
test method
Prior art date
Application number
AT94103057T
Other languages
English (en)
Inventor
Akihiko Takashima
Toshimitsu Hoshino
Kazutomo Imahori
Ken-Ichi Saito
Akiko Shiratsuchi
Showbu Sato
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27290732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE254172(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP5041160A external-priority patent/JPH06253835A/ja
Priority claimed from JP5191246A external-priority patent/JPH06329551A/ja
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Application granted granted Critical
Publication of ATE254172T1 publication Critical patent/ATE254172T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11026—Tau-protein kinase (2.7.11.26)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT94103057T 1993-03-02 1994-03-01 Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase ATE254172T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP5041160A JPH06253835A (ja) 1993-03-02 1993-03-02 ヒト由来タウプロテインキナーゼｉ、それをコードする遺伝子及びその産生方法
JP8514393 1993-03-22
JP5191246A JPH06329551A (ja) 1993-03-22 1993-08-02 アルツハイマー病の予防または治療薬およびそのスクリーニング方法

Publications (1)

Publication Number Publication Date
ATE254172T1 true ATE254172T1 (de) 2003-11-15

Family

ID=27290732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94103057T ATE254172T1 (de) 1993-03-02 1994-03-01 Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase

Country Status (4)

Country Link
EP (1) EP0616032B2 (de)
AT (1) ATE254172T1 (de)
CA (1) CA2116460A1 (de)
DE (1) DE69433309T3 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2195672A1 (en) * 1994-07-29 1996-02-15 Eugeen Vanmechelen Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
JP4194117B2 (ja) * 1995-12-21 2008-12-10 サニーブルック ヘルス サイエンスセンター インテグリン結合キナーゼ（ｉｎｔｅｇｒｉｎ―ｌｉｎｋｅｄ ｋｉｎａｓｅ）、その阻害剤およびこれらの阻害剤を用いる医学的治療の方法、遺伝子治療ならびに偽基質阻害剤
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
EP1019043A4 (de) * 1996-05-07 2003-07-30 Univ Pennsylvania Inhibitoren der glykogensynthese-kinase 3 und verfahren zu ihrer identifizierung und verwendung
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US6071493A (en) 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
WO2000017184A1 (en) * 1998-09-24 2000-03-30 Mitsubishi Chemical Corporation Hydroxyflavone derivatives as tau protein kinase 1 inhibitors
US7314864B1 (en) * 1999-09-17 2008-01-01 Keio University Humanin, a polypeptide suppressing neuronal death
US6323029B1 (en) * 2000-01-19 2001-11-27 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression
WO2001082967A1 (fr) * 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees a supprimer la production de ?-amyloide
CA2417277A1 (en) 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
GB0605337D0 (en) 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
WO2007127273A2 (en) * 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
MX2010002765A (es) 2007-09-14 2010-05-19 Mitsubishi Tanabe Pharma Corp Derivado de 6-pirimidinil-pirimid-4-ona.
EP2078717A1 (de) 2008-01-11 2009-07-15 sanofi-aventis 6-Pyrimidinyl-Pyrimid-2-One-Derivate
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
JP5442852B2 (ja) 2009-08-13 2014-03-12 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
US9006232B2 (en) 2009-08-13 2015-04-14 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives
TWI702046B (zh) 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
KR20250112919A (ko) 2015-12-21 2025-07-24 노파르티스 아게 타우 발현을 감소시키기 위한 조성물 및 방법
EP4567427A4 (de) * 2022-09-01 2026-07-22 Shanghai Raising Pharmaceutical Co Ltd Biomarker und zugehöriger nachweiskit für morbus alzheimer

Also Published As

Publication number Publication date
EP0616032A3 (de) 1996-12-11
CA2116460A1 (en) 1994-09-03
DE69433309T3 (de) 2007-08-30
DE69433309T2 (de) 2004-09-16
EP0616032B1 (de) 2003-11-12
EP0616032A2 (de) 1994-09-21
EP0616032B2 (de) 2007-02-14
DE69433309D1 (de) 2003-12-18

Similar Documents

Publication Publication Date Title
DE69433309D1 (de) Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase
DE59307474D1 (de) Verwendung von wasserlöslichen oder in wasser dispergierbaren polyurethanen als hilfsmittel in kosmetischen und pharmazeutischen zubereitungen und polyurethane, die polymilchsäurepolyole einpolymerisiert enthalten
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
DE69400333D1 (de) Kosmetische und dermatologische Zusammensetzungen, die eine Kombination aus Ceramiden und Linolsäure enthalten
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69407419D1 (de) 2' oder 3' -deoxy- und 2' -dideoxy-beta-l-pentafuranonukleoside, verfahren zur herstellung und anwendung in der therapie, insbesondere als antivirale wirkstoffe
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
ATE179888T1 (de) Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure
ATE290385T1 (de) Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten
ATE240725T1 (de) Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten
Gustafson et al. Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE68903059D1 (de) Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten.
IT9020968A0 (it) Metodi e composizioni farmaceutiche per il trattamento di malattie oftalmiche
Juhlin et al. Acrivastine Versus Clemastine in the Treatment of Chronic Idiopathic Urticaria.
PT90677A (pt) Processo para a preparacao de novas diazepinonas condensadas e de composicoes farmaceuticas que as contem
DE3775854D1 (de) Arzneimittel zur therapie von durch funktionelle und organische basen verursachten gehirnkrankheiten.
BR9506838A (pt) Derivados de ácido micofenólico substituídos na posição 5
ATE6256T1 (de) N-(4-phenyl-2-thiazolyl)-oxamidsaeure-2ethoxyethylester, verfahren zu seiner herstellung und diesen enthaltende therapeutische mittel.
DE3784738D1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties